Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial.
about
Molecular landscape of acute myeloid leukemia in younger adults and its clinical relevanceMaintenance therapy with all-trans retinoic acid and arsenic trioxide improves relapse-free survival in adults with low- to intermediate-risk acute promyelocytic leukemia who have achieved complete remission after consolidation therapy.Acute promyelocytic leukemia with a cryptic insertion of RARA into PML on chromosome 15 due to uniparental isodisomy: A case report.LG-362B targets PML-RARα and blocks ATRA resistance of acute promyelocytic leukemia.All-Trans Retinoic Acid plus Arsenic Trioxide versus All-Trans Retinoic Acid plus Chemotherapy for Newly Diagnosed Acute Promyelocytic Leukemia: A Meta-Analysis.Molecular Monitoring as a Path to Cure Acute Promyelocytic LeukemiaMassive Pulmonary Embolism at the Onset of Acute Promyelocytic LeukemiaPrognostic Significance of Mixed-Lineage Leukemia (MLL) Gene Detected by Real-Time Fluorescence Quantitative PCR Assay in Acute Myeloid Leukemia.Bayesian network meta-analysis comparing five contemporary treatment strategies for newly diagnosed acute promyelocytic leukaemia.Induction treatments for acute promyelocytic leukemia: a network meta-analysis.Retinoic acid and arsenic trioxide in the treatment of acute promyelocytic leukemia: current perspectives.Recent advances in acute promyelocytic leukaemia.Acute myeloid leukemia--major progress over four decades and glimpses into the future.Current standard treatment of adult acute promyelocytic leukaemia.The evolving role of chemotherapy and hematopoietic cell transplants in Ph-positive acute lymphoblastic leukemia in adults.Acute myeloid leukemia in the elderly: therapeutic options and choice.Gemtuzumab ozogamicin in acute myeloid leukemia.Repression of CDKN2C caused by PML/RARα binding promotes the proliferation and differentiation block in acute promyelocytic leukemia.Chemosensitivity enhancement toward arsenic trioxide by inhibition of histone deacetylase in NB4 cell line.Leukostasis in adult acute hyperleukocytic leukemia: a clinician's digest.Current management of newly diagnosed acute promyelocytic leukemia.DNA Repair in Despair-Vitamin D Is Not Fair.Characteristics and outcome of patients with therapy-related acute promyelocytic leukemia front-line treated with or without arsenic trioxide.Beyond Anthracyclines: Preemptive Management of Cardiovascular Toxicity in the Era of Targeted Agents for Hematologic Malignancies.Non-inferiority trials: No better? No worse? No change? No pain?Preventing relapse after haematopoietic stem cell transplantation for acute leukaemia: the role of post-transplantation minimal residual disease (MRD) monitoring and MRD-directed intervention.Telomere Length Recovery: A Strong Predictor of Overall Survival in Acute Promyelocytic Leukemia.Long-term outcome of acute promyelocytic leukemia treated with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab.Arsenic Trioxide and Tretinoin (AsO/ATRA) for Acute Promyelocytic Leukemia (APL).Treatment of older patients with acute myeloid leukemia (AML): revised Canadian consensus guidelines.Meta-Analysis of Gene Expression Profiles in Acute Promyelocytic Leukemia Reveals Involved Pathways.Pml nuclear body disruption cooperates in APL pathogenesis and impairs DNA damage repair pathways in mice.Metformin ameliorates arsenic trioxide hepatotoxicity via inhibiting mitochondrial complex I.Inhibition of STAT3/VEGF/CDK2 axis signaling is critically involved in the antiangiogenic and apoptotic effects of arsenic herbal mixture PROS in non-small lung cancer cells.Progress and criticalities in the management of acute promyelocytic leukemia.Early death rates remain high in high-risk APL: update from the Swedish Acute Leukemia Registry 1997-2013.Frontline therapy of acute promyelocytic leukemia: Randomized comparison of ATRA and intensified chemotherapy versus ATRA and anthracyclines.Detection and Quantification of Acute Myeloid Leukemia-Associated Fusion Transcripts.First experience of the AML-Berlin-Frankfurt-Münster group in pediatric patients with standard-risk acute promyelocytic leukemia treated with arsenic trioxide and all-trans retinoid acid.Long-term outcome of older patients with newly diagnosed de novo acute promyelocytic leukemia treated with ATRA plus anthracycline-based therapy.
P2860
Q26776393-E258286D-5077-45EC-851B-1ACC76A5504AQ33631350-314EC66C-9220-4323-97A7-508AFD97DA1FQ33751316-AF8E8002-0DCF-4A22-8A2E-5A0192B3905FQ35969759-0F007168-607A-4C3B-AF1B-15EC6BCE2897Q36070904-D97541EA-3223-4BE5-AFCC-EA69B0D6236EQ36816685-E3F55AB9-3AB2-404A-BE30-1A4F276BEFF8Q37055381-1B192228-34C0-43D1-AE9D-0C71CF46BA7BQ37234433-159E2DA5-6B32-4CA0-9CE8-8B076B8E418EQ37565126-31EFC130-DE9B-4F2D-9CB7-D3B73715F334Q37687750-CCE9F6C0-C1F5-46E2-ABC9-B4637163FD85Q37712353-D8EC6B2D-81A7-4E3E-9FC3-50C70AE16BD8Q38556985-A0B55557-0A92-4440-874D-805F0B0B0851Q38644941-DD313312-1B3D-459A-A0B4-9AC4BAD27E2DQ38674575-624BADA7-4938-4937-BDD9-E3BBB110D3FFQ38674733-08C22824-0E0B-4A64-82EC-00C680ED29D3Q38675781-A5F1531A-1AB7-4ADE-9B41-73E7D9E24A40Q38728718-A383715F-1516-4168-9D9C-32068284459BQ38728895-D772A171-9368-4E4B-A0A4-368FD2A5C9BDQ38770298-88C8E407-8CF2-44EF-B474-165886F2DD69Q38790500-43640C12-FB1D-443C-B0DD-0C4B7F8F75FEQ38809825-6292E926-4A1F-49BF-A2AA-0493FC89E1E8Q38874859-18A4A970-9149-4EFB-8E19-46681DF4D4EDQ38891536-1746125F-A076-427B-8E60-28AD04845787Q38944823-5EBBB19A-22F1-4E15-BAF3-E08BC256543AQ39096602-62368B3A-C0CA-4C96-9E48-7562A8CFD0E7Q39329093-AC86D7AF-A9B1-4AF0-A3EB-5AE46DAA128BQ40269702-98541E2E-B8FF-4F60-B61E-F5D352808867Q40413191-3230D0CF-98FF-4F69-BA56-FEDB122819DEQ41141216-6C5EA958-E866-49A4-B0B2-0616B6385CF4Q41265804-404F7952-592D-49F0-8205-CB053F8F8274Q42044605-3E7DA52D-3209-4640-B250-CEF4E8439DA2Q45974271-11667192-C6D9-4EB5-B705-2FEC551AA097Q46270264-4C463DA3-1DB0-4B1A-BE6C-1DA671C418EAQ47118750-A848A5B4-B2FD-439F-95D5-16FC85DE2461Q47160338-5D862E04-2A25-4DAE-876C-AD25E061BF05Q48200551-BDBFBB96-8838-4EE3-A120-14D1E5CEF58DQ48346019-80A313A2-E1EA-4BF1-907D-6FB85409C9E3Q48714437-B35C9633-E11C-4987-BB0D-F96AE1DD4B01Q50861872-9407AAC5-2F4E-4E58-A8F9-0283C5C86D95Q53486790-8DAA6F64-8CAA-4AF8-AA7E-E917D2B3F58D
P2860
Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Arsenic trioxide and all-trans ...... ed, controlled, phase 3 trial.
@en
type
label
Arsenic trioxide and all-trans ...... ed, controlled, phase 3 trial.
@en
prefLabel
Arsenic trioxide and all-trans ...... ed, controlled, phase 3 trial.
@en
P2093
P1433
P1476
Arsenic trioxide and all-trans ...... ed, controlled, phase 3 trial.
@en
P2093
Alan K Burnett
Angela Grech
Ann Hunter
Asim Khwaja
David Bowen
David Grimwade
Gail Jones
Jennie Lok
Jonathan Kell
Lone Friis
P304
P356
10.1016/S1470-2045(15)00193-X
P577
2015-09-14T00:00:00Z